ZA911471B - The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity - Google Patents

The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity

Info

Publication number
ZA911471B
ZA911471B ZA911471A ZA911471A ZA911471B ZA 911471 B ZA911471 B ZA 911471B ZA 911471 A ZA911471 A ZA 911471A ZA 911471 A ZA911471 A ZA 911471A ZA 911471 B ZA911471 B ZA 911471B
Authority
ZA
South Africa
Prior art keywords
pny
preparation
antagonistic activity
guanidine derivatives
pharmaceutical product
Prior art date
Application number
ZA911471A
Other languages
English (en)
Inventor
Martin C Dr Michel
C Michel Dr Martin
Johan Peter Dr Moersdorf
Peter Moersdorf Dr Johan
Heidrun Dr Engler
Engler Dr Heidrun
Helmut Dr Schickaneder
Schickaneder Dr Helmut
Kurt-Henning Dr Ahrens
Ahrens Dr Kurt-Henning
Original Assignee
Heumann Pharma Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heumann Pharma Gmbh & Co filed Critical Heumann Pharma Gmbh & Co
Publication of ZA911471B publication Critical patent/ZA911471B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
ZA911471A 1990-03-30 1991-02-28 The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity ZA911471B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90106200A EP0448765B1 (de) 1990-03-30 1990-03-30 Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung

Publications (1)

Publication Number Publication Date
ZA911471B true ZA911471B (en) 1991-11-27

Family

ID=8203843

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA911471A ZA911471B (en) 1990-03-30 1991-02-28 The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity

Country Status (14)

Country Link
EP (1) EP0448765B1 (da)
JP (1) JPH0789939A (da)
KR (1) KR910016329A (da)
AT (1) ATE109979T1 (da)
AU (1) AU637882B2 (da)
CA (1) CA2037433A1 (da)
DE (1) DE59006842D1 (da)
DK (1) DK0448765T3 (da)
ES (1) ES2058651T3 (da)
HU (1) HU207945B (da)
IE (1) IE65252B1 (da)
IL (1) IL97424A (da)
PT (1) PT97138A (da)
ZA (1) ZA911471B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08501055A (ja) * 1991-12-19 1996-02-06 ガーヴァン インスティチュート オブ メディカル リサーチ 神経ペプチドチロシンの生物学的機能を抑制する新規な分子
US5516653A (en) * 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) * 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) * 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
AU7692996A (en) * 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
WO1997020822A1 (en) * 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
WO1997043278A1 (en) * 1996-05-14 1997-11-20 Novo Nordisk A/S Somatostatin agonists and antagonists
AU4159297A (en) * 1996-08-23 1998-03-06 Agouron Acquisition Corp. Neuropeptide-y ligands
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
EP0937065A1 (en) * 1996-10-31 1999-08-25 Novo Nordisk A/S Constrained somatostatin agonists and antagonists
AU6267198A (en) * 1997-02-14 1998-09-08 Bayer Corporation Amides as npy5 receptor antagonists
US6048900A (en) * 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
WO1998035957A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
BR9810651A (pt) * 1997-07-03 2000-10-03 Neurogen Corp Certos derivados de diarilimidazol; uma nova classe de ligantes npy especìficos
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AU2935200A (en) 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
WO2002024657A2 (en) 2000-09-20 2002-03-28 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
CA2422729A1 (en) 2000-09-20 2002-06-06 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
AU2001292723A1 (en) * 2000-09-20 2002-04-02 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
AU2001292730A1 (en) 2000-09-20 2002-04-02 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199845B1 (de) * 1985-04-02 1990-08-01 HEUMANN PHARMA GMBH & CO Imidazolylalkylguanidinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3631334A1 (de) * 1986-09-15 1988-03-17 Heumann Pharma Gmbh & Co Neue imidazolylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Also Published As

Publication number Publication date
DE59006842D1 (de) 1994-09-22
HUT57044A (en) 1991-11-28
HU910979D0 (en) 1991-10-28
IE910995A1 (en) 1991-10-09
DK0448765T3 (da) 1994-09-19
ATE109979T1 (de) 1994-09-15
EP0448765A1 (de) 1991-10-02
IL97424A0 (en) 1992-06-21
AU637882B2 (en) 1993-06-10
PT97138A (pt) 1991-11-29
ES2058651T3 (es) 1994-11-01
CA2037433A1 (en) 1991-10-01
KR910016329A (ko) 1991-11-05
JPH0789939A (ja) 1995-04-04
EP0448765B1 (de) 1994-08-17
HU207945B (en) 1993-07-28
AU7206891A (en) 1991-10-03
IE65252B1 (en) 1995-10-18
IL97424A (en) 1995-05-26

Similar Documents

Publication Publication Date Title
IL97424A0 (en) Use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity
CA2122612A1 (en) Pharmaceutical products for curing tumourous diseases and process for preparing same
AU2506388A (en) Azelastine-containing medicaments for application in the nose and/or at the eye
CA2041579A1 (en) Dosage form
ATE163849T1 (de) Arzneimittel enthaltend als wirkstoff r-alpha- liponsäure oder s-alpha-liponsäure
HU913283D0 (en) Process for the production of hydroximethyl-(methylene-cyclopentyl)-purines and pirimidines, their medically usable salts, and of medical preparations containing them
CS189391A3 (en) Dialkoxypiridylbenzimidazole derivatives, process of their preparation and their pharmaceutical use
HU912266D0 (en) Process for the production of solid medical preparations with controlled portioning of the active agents for oral use
HU9300636D0 (en) Medical preparatives, method for producing them and their applications as analgetic and/or febrifuge in human and veterinary medicine
FI935693A7 (fi) Bifenyylin johdannaiset, niiden valmistus ja käyttö korkean verenpaineen ja sydäntautien hoitoon
AU1968992A (en) Preparation of fatty acid medicaments
GR3006091T3 (da)
HU913137D0 (en) 2-amino-4-carboxamido-pirimidine derivatives, their production and medical use
HU911756D0 (en) Process for the production of medical preparations containing magnesium-pyridoxal-5'-phosphate-glutaminate, for the preventing of arterial diseases
ATE162076T1 (de) Verwendung von nadh und nadph zur herstellung eines arzneimittels zur behandlung von morbus alzheimer
NZ332105A (en) Medicaments including human growth hormone for the treatment of type II diabetes and metabolic syndrome
ATE122883T1 (de) Arzneimittel enthaltend ranitidin/wismutcarboxylat-salze.
EP0732401A3 (en) Megacaryocyte stimulating factor (meg-CSF)
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
EP0651741A1 (en) DERIVATIVES OF N? G -MONOMETHYL-L-ARGININE HYDROCHLORIDE AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK.
NO890997L (no) Applikator for hudrensemiddel, hudpleiemiddel og medisinsk salve.
EP0418065A3 (en) Dihydrocaffeic acid derivatives, use thereof for medical treatments and pharmaceutical preparations containing same
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
EP0360191A3 (en) Anti-aids virus composition
CA2064112A1 (en) .alpha.-dihydroergocryptine pharmaceutical preparations with neuroprotective activity